Determination of the RANKL/Osteoprotegerin Ratio in Patients With Systemic Lupus Erythematosus. Role in Osteoporosis and Cardiovascular Calcification
This trial is active, not recruiting.
|Conditions||osteoporosis, lupus erythematosus, systemic|
|Treatments||rankl/opg ratio, bone densitometry, fan beam ct scan, doppler ultrasound|
|Sponsor||Centre Hospitalier Universitaire, Amiens|
|Start date||April 2011|
|End date||April 2017|
|Trial size||74 participants|
|Trial identifier||NCT02799173, PHRCIR09-PR-MAZIERE-MME|
Patients with Systemic lupus erythematosus (SLE) are known to present an increased risk of osteoporosis and cardiovascular calcification. It has also been suggested that bone remodelling and cardiovascular calcification are regulated by the same mechanisms, but inversely in terms of calcium deposition, as osteoporosis is often associated with cardiovascular calcification. Inflammatory and immune factors have been implicated in these two processes.
The role of the RANKL/OPG system in osteoclast differentiation has been elucidated over the last ten years. RANKL induces differentiation of monocytes-macrophages into osteoclasts, while, inversely, OPG exerts an inhibitory role by inactivating RANKL. Differentiation of smooth muscle cells into osteoblasts in the vessel wall induces calcification, and this phenomenon is counterbalanced by differentiation of monocytes into osteoclasts. Although the role of the RANKL/OPG ratio in the pathogenesis of osteoporosis has now been clearly established, its role in vascular calcification is only hypothetical at the present time.
This study will focus on patients with SLE diagnosed and followed in the Amiens University Hospital Internal Medicine and Nephrology departments
|Intervention model||single group assignment|
|Primary purpose||basic science|
RANKL/OPG ratio bone densitometry fan beam CT scan Doppler ultrasound
time frame: Day 0
presence of osteoporosis
time frame: Day 0
Female participants from 18 years up to 99 years old.
- Women over 18 years old
- suffering from systemic lupus erythematosus.
- Malignancies such as cancer metastasized
- Autoimmune disease other than LED or of overlap syndrome ( rhupus , MCTD )
- Infection by HIV, hepatitis B and C
- Hepatic Cirrhosis
- Chronic renal failure
- Parathyroid disorders
|Official title||Determination of the RANKL/Osteoprotegerin Ratio in Patients With Systemic Lupus Erythematosus. Role in Osteoporosis and Cardiovascular Calcification|
|Principal investigator||Cécile MAZIERE, Md, PhD|
Call for more information